Table 2 Applications of 2D nanomaterials in neurological disorders

Alzheimer’s disease

TPP-MoS2 QDs

In vitro

Mitigate Aβ aggregate-mediated neurotoxicity and eliminate Aβ aggregates

Treatment

[137]

PEG-LK7@BP

In vitro

Suppress Aβ₄₂ conformational transformation from random coil into β-sheet structures

Treatment

[138]

Dau-GO

In vitro

/in vivo

Exert antioxidant and anti-glial aggregation effects

Treatment

[139]

Parkinson’s disease

NiAl LDH/G LBL

In vitro

Track DA from neuronal cell in real-time

Diagnosis

[140]

MoS2-CPBNPs

-

Potential DA probes

Diagnosis

[141]

Lf-BP-Pae

In vitro

/in vivo

Inhibit neuronal damage; increased the translocation abilities of Lf-BP-Pae across the BBB with near-infrared irradiation

Treatment

[142]

Huntington’s disease

siRNAs-LDH

In vitro

Promote the ability of siRNAs to target and destroy specific mRNAs

Treatment

[143]

GO

In vitro

Enhance autophagic flow and increase ubiquitination of Htt protein

Treatment

[144]

Traumatic brain injury

GO-pSiNPs

In vitro

/in vivo

Gene silence and trauma localization

Treatment

[145]

CFGO

In vitro

/in vivo

Exhibit significant neuro-regeneration potential, promote fast brain regeneration in mice with sham injuries, enhance reactive astrocytes in the hippocampal dentate gyrus after sham injury

Treatment

[146]

Spinal cord injury

PLGA/GO

In vitro

Reduce oxidative stress, promote differentiation of NSCs, and enhance their survival and differentiation

Treatment

[147]

rGO-MFs

In vivo

Promote axonal and vascular regeneration in injured spinal cords

Treatment

[148]